Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

dechra vet products, llc - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - indications: enrofloxacin injectable solution is indicated for the management of diseases in dogs associated with bacteria susceptible to enrofloxacin. contraindications: enrofloxacin is contraindicated in dogs known to be hypersensitive to quinolones. based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or giant breeds.

Spanien - Englisch - HMA (Heads of Medicines Agencies)

global vet health sl - enrofloxacin 100 mg - oral solution - chicken, turkeys - enrofloxacin

Ungarn - Englisch - HMA (Heads of Medicines Agencies)

global vet health sl - enrofloxacin 100 mg - oral solution - chicken, turkeys - enrofloxacin

Portugal - Englisch - HMA (Heads of Medicines Agencies)

global vet health sl - enrofloxacin 100 mg - oral solution - chicken, turkeys - enrofloxacin

Rumänien - Englisch - HMA (Heads of Medicines Agencies)

global vet health sl - enrofloxacin 100 mg - oral solution - chicken, turkeys - enrofloxacin

Irland - Englisch - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - enrofloxacin - infus/pdr/oral soln - 100 mg/ml - enrofloxacin - fowl - chicken, fowl - turkey - antibacterial

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

elanco us inc. - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn), silver sulfadiazine (unii: w46jy43ejr) (sulfadiazine - unii:0n7609k889) - baytril otic is indicated as a treatment for canine otitis externa complicated by bacterial and fungal organisms susceptible to enrofloxacin and/or silver sulfadiazine (see microbiology section). baytril otic is contraindicated in dogs with suspected or known hypersensitivity to quinolones and/or sulfonamides.

Malaysia - Englisch - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

kami farming sdn. bhd. - enrofloxacin -

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

novartis animal health us, inc. - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin 22.7 mg

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

bayer healthcare llc animal health division - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin 22.7 mg - baytril® (brand of enrofloxacin) antibacterial tablets are indicated for the management of diseases associated with bacteria susceptible to enrofloxacin. baytril antibacterial tablets are indicated for use in dogs and cats. enrofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones. dogs: based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or giant breeds.